HOUSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- IFM Investors Pty Ltd (“IFM”) and Buckeye Partners, L.P. (“Buckeye”) today announced the completion of the acquisition of Buckeye by entities affiliated with ...

Aspiring to become the leader in inflammasome-targeted therapeutics, Novartis will acquire IFM Tre, a subsidiary of Boston-based IFM Therapeutics, in a deal worth up to $1.6 billion. The purchase ...

Bemoaning a lack of big infrastructure projects in Australia, the industry superannuation owned IFM Investors fund has looked overseas to seal a $15 billion deal to buy US oil pipeline business ...

Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the ...

Novartis AGNVS announced that it will acquire IFM Tre, a subsidiary of IFM Therapeutics LLC. The acquisition will add a broad portfolio of immunomodulatory medicines, focused on developing ...

It’s the lucky biotech that has a short and sweet runway. Most companies bring a drug to market — and begin to bring in revenue — only after years or decades of work. But a company backed by Atlas ...

Buckeye Partners L.P. said Friday it has agreed to be acquired by IFM Investors in an all-cash deal with an enterprise value of $10.3 billion and equity value of $6.5 billion. IFM will pay $41.50 per ...

IFM Therapeutics LLC, an innate immunity specialist that's quickly sparked major deals with big pharma, is stoking the generative fire at its heart with $55.5 million in new financing led by ...

In their search for new ways to treat cancer, biotech firms are learning more about the immune system than ever before. The red hot strategy of activating the immune system to treat cancer is leading ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3pdzsk/global_ifm_market) has announced the addition of the "Global IFM ...